Sohini Das, Anjali Singh

Stories by Sohini Das, Anjali Singh

Biocon eyes in-licensing to boost biosimilars portfolio, targets margin expansion

Biocon eyes in-licensing to boost biosimilars portfolio, targets margin expansion

Rediff.com   3 days ago

Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.

Bajaj Auto gears up for festival season with new Pulsar models

Bajaj Auto gears up for festival season with new Pulsar models

Rediff.com   4 days ago

Bajaj Auto is set to launch new Pulsar motorcycles in the 125cc and 150-250cc segments in Q2 FY27, aiming to capitalise on the upcoming festival season surge. This move follows strong growth in the 150cc-plus segment, where refreshed Pulsar models already account for over 50 per cent of Bajaj's sales.

Piramal Pharma looks to return on growth path

Piramal Pharma looks to return on growth path

Rediff.com   4 days ago

Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.

M&M refines supply chain strategy to counter global disruptions

M&M refines supply chain strategy to counter global disruptions

Rediff.com   5 days ago

Mahindra & Mahindra (M&M) is implementing a comprehensive, multi-layered strategy to fortify its supply chains against geopolitical volatility, logistical challenges, and regulatory risks, drawing lessons from recent global disruptions.

Bajaj Auto's Q4 Profit More Than Doubles Amid Record Sales and KTM Consolidation

Bajaj Auto's Q4 Profit More Than Doubles Amid Record Sales and KTM Consolidation

Rediff.com   5 days ago

Bajaj Auto reported a significant increase in its consolidated Q4FY26 performance, with profit after tax more than doubling to approximately 3,662 crore, a 103 per cent year-on-year rise, primarily driven by record volumes, an improved product mix, and the strategic consolidation of Bajaj Auto International Holdings AG (BAIHAG).

Biocon Succession Plan: Kiran Mazumdar-Shaw Names Claire Mazumdar as Future Leader

Biocon Succession Plan: Kiran Mazumdar-Shaw Names Claire Mazumdar as Future Leader

Rediff.com   6 days ago

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon. Explore the leadership transition, strategy, and future plans.

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Chinese API price surge tests India's pharma buffers amid West Asia crisis

Rediff.com   2 May 2026

India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.

Maruti Suzuki discontinues Ignis hatchback amid weak sales, supply woes hit S-Presso and WagonR

Maruti Suzuki discontinues Ignis hatchback amid weak sales, supply woes hit S-Presso and WagonR

Rediff.com   30 Apr 2026

Maruti Suzuki has discontinued its Ignis hatchback due to weak sales and a shift towards SUVs, while simultaneously facing supply chain issues for its popular S-Presso and WagonR models, leading to booking halts at some dealerships.

Electric Motorcycles Gain Traction, But Scaling Remains A Challenge

Electric Motorcycles Gain Traction, But Scaling Remains A Challenge

Rediff.com   27 Apr 2026

India's electric motorcycle market is experiencing significant growth, with a 28 per cent year-on-year increase in volumes, as new product launches and improved total cost of ownership attract a broader base of riders beyond early adopters.

Mid-Size SUVs Fuel 87% Surge in India's EV Sales in FY26

Mid-Size SUVs Fuel 87% Surge in India's EV Sales in FY26

Rediff.com   27 Apr 2026

India's electric passenger vehicle market saw an 87.4 per cent year-on-year increase in FY26, reaching 233,246 units, primarily driven by the mid-size SUV segment (20-30 lakh price bracket), while the entry-level segment (sub-10 lakh) experienced a decline.

Volkswagen bets big on India, targets 5% market share

Volkswagen bets big on India, targets 5% market share

Rediff.com   21 Apr 2026

koda Auto Volkswagen India aims to capture a 5 per cent share of India's passenger vehicle market by 2030, driven by new product launches, including alternate fuel vehicles, and a potential entry into the high-volume sub-4 metre SUV segment.

Slimming Drug Boom Sparks Misuse Concerns: 'They Are Not Meant For Cosmetic Weight Loss'

Slimming Drug Boom Sparks Misuse Concerns: 'They Are Not Meant For Cosmetic Weight Loss'

Rediff.com   20 Apr 2026

The fast-growing GLP-1 market, propelled by lower-cost generics following patent expiry, is widening availability beyond patients with obesity and diabetes -- but also driving unsupervised, appearance-led demand, according to doctors.

Exporters' body flags rising freight costs, seeks liquidity help from RBI

Exporters' body flags rising freight costs, seeks liquidity help from RBI

Rediff.com   18 Apr 2026

The Federation of Indian Export Organisations (FIEO) has appealed to the Reserve Bank of India (RBI) for liquidity support to Indian exporters, citing a significant increase in freight costs and extended payment cycles due to the ongoing West Asia conflict.

Silent Diseases Hit Young India

Silent Diseases Hit Young India

Rediff.com   16 Apr 2026

Young adults show alarming NCD trends, with high rates of obesity, prediabetes, and abnormal cholesterol levels.

Electric scooters set to dominate India's two-wheeler market by 2037, outpacing motorcycles

Electric scooters set to dominate India's two-wheeler market by 2037, outpacing motorcycles

Rediff.com   14 Apr 2026

India's two-wheeler market is on the cusp of a significant transformation, with electric scooters projected to surpass motorcycles in volume terms within the next decade, driven by urbanisation, increased female workforce participation, and the accelerating shift towards electrification, according to an Equirus Securities report.

Tata Motors leads PV recovery in H2

Tata Motors leads PV recovery in H2

Rediff.com   13 Apr 2026

Tata Motors emerged as the biggest gainer in the passenger vehicles (PV) market in the second half of FY25, following a GST rate cut in September, achieving the highest growth among major OEMs and overtaking Mahindra & Mahindra in volumes.

After GST-led surge, car sales growth may decelerate in FY27

After GST-led surge, car sales growth may decelerate in FY27

Rediff.com   13 Apr 2026

India's passenger vehicle (PV) industry is projected to experience moderated growth in FY27, following a strong rebound in H2FY26, primarily due to the high base effect, absorbed pent-up demand, and the lingering impact of geopolitical tensions in West Asia.

Top end luxury cars power Mercedes over entry-level models

Top end luxury cars power Mercedes over entry-level models

Rediff.com   13 Apr 2026

What we will not do is discount deeply, neither will we compromise on product substance, says Managing Director and Chief Executive Officer (MD&CEO) Santosh Iyer.

Tesla Stalls in India as BYD, VinFast Race Ahead

Tesla Stalls in India as BYD, VinFast Race Ahead

Rediff.com   10 Apr 2026

Despite India's electric passenger vehicle market experiencing an 83.6% year-on-year surge in FY26, new foreign entrants VinFast and BYD have significantly outpaced Tesla, which struggles with high import duties, a limited retail footprint, and a lack of local manufacturing commitment.

Indian Pharma Market Records Strongest Q4 Growth in Five Quarters

Indian Pharma Market Records Strongest Q4 Growth in Five Quarters

Rediff.com   9 Apr 2026

India's domestic pharmaceutical market recorded its highest value growth in five quarters during Q4 FY26, driven primarily by pricing and an early indication of volume recovery, with a significant structural shift towards chronic and sub-chronic therapies.